BTNL2, a Butyrophilin/B7-Like Molecule, Is a Negative Costimulatory Molecule Modulated in Intestinal Inflammation
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Butyrophilin-like 2 (BTNL2) is a butyrophilin family member with homology to the B7 costimulatory molecules, polymorphisms of which have been recently associated through genetic analyses to sporadic inclusion body myositis and sarcoidosis. We have characterized the full structure, expression, and function of BTNL2. Structural analysis of BTNL2 shows a molecule with an extracellular region containing two sets of two Ig domains, a transmembrane region, and a previously unreported cytoplasmic tail. Unlike most other butyrophilin members, BTNL2 lacks the prototypical B30.2 ring domain. TaqMan and Northern blot analysis indicate BTNL2 is predominantly expressed in digestive tract tissues, in particular small intestine and Peyer’s patches. Immunohistochemistry with BTNL2-specific Abs further localizes BTNL2 to epithelial and dendritic cells within these tissues. Despite its homology to the B7 family, BTNL2 does not bind any of the known B7 family receptors such as CD28, CTLA-4, PD-1, ICOS, or B and T lymphocyte attenuator. Because of its localization in the gut and potential role in the immune system, BTNL2 expression was analyzed in a mouse model of inflammatory bowel disease. BTNL2 is overexpressed during both the asymptomatic and symptomatic phase of the Mdr1a knockout model of spontaneous colitis. In functional assays, soluble BTNL2-Fc protein inhibits the proliferation of murine CD4+ T cells from the spleen, mesenteric lymph node, and Peyer’s patch. In addition, BTNL2-Fc reduces proliferation and cytokine production from T cells activated by anti-CD3 and B7-related protein 1. These data suggest a role for BTNL2 as a negative costimulatory molecule with implications for inflammatory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“A second inhibitory receptor PD-1 (10, 11) binds to either of two B7-related ligands PD-L1 (also known as B7-H1) (12, 13) and PD-L2 (or B7-DC) (14, 15).”
BackgroundPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · cited 1×
“A second inhibitory receptor PD-1 (10, 11) binds to either of two B7-related ligands PD-L1 (also known as B7-H1) (12, 13) and PD-L2 (or B7-DC) (14, 15).”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · cited 1×
“A second inhibitory receptor PD-1 (10, 11) binds to either of two B7-related ligands PD-L1 (also known as B7-H1) (12, 13) and PD-L2 (or B7-DC) (14, 15).”
BackgroundGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 2×
“Disruption of this pathway has been beneficial in regulating autoimmunity in a number of mouse models of disease, including colitis, multiple sclerosis, and arthritis (1, 39).”
BackgroundICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · cited 1×
“Mice lacking either BTLA or PD-1 are predisposed to develop autoimmune phenotypes with signs of progressive arthritis and glomerulonephritis, suggesting their roles in the inhibition of inflammatory responses and in maintaining peripheral tolerance (11, 41), therefore it is possible that mice lacking BTNL2 might be mo…”
BackgroundMurine B7-H3 is a negative regulator of T cells
Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2500 · Cited by 368 · cited 1×
“B7-H3, another B7 homolog (16, 17), binds an unidentified receptor on activated T cells and serves as a negative regulator of T cell activation (18).”
Background
Cited by
Iannuzzi, M. C., Rybicki, B. A., & Teirstein, A. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071714 · Cited by 1,968
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
γδ T cells in homeostasis and host defence of epithelial barrier tissues
Nielsen, M. M., Witherden, D. A., & Havran, W. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.101 · Cited by 479
Epithelial decision makers: in search of the 'epimmunome'
Swamy, M., Jamora, C., Havran, W., & Hayday, A. (2010) · Nature Immunology · doi:10.1038/ni.1905 · Cited by 269
Animal Models of Inflammatory Bowel Disease
(2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-394596-9.00009-3 · Cited by 267
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases
International MHC and Autoimmunity Genetics Network (IMAGEN)*, Rioux, J. D., Goyette, P., Vyse, T. J., Hammarström, L., Fernando, M. M. A., Green, T., De Jager, P. L., Foisy, S., Wang, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909307106 · Cited by 256
and the IBSEN study group, Franke, A., Balschun, T., Sina, C., Ellinghaus, D., Häsler, R., Mayr, G., Albrecht, M., Wittig, M., Buchert, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.553 · Cited by 194
Yin–Yang of costimulation: crucial controls of immune tolerance and function
Nurieva, R. I., Liu, X., & Dong, C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00769.x · Cited by 157
Human γδ T-Cell Control of Mucosal Immunity and Inflammation
McCarthy, N. E., & Eberl, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00985 · Cited by 96
“Intriguingly, BTNL2 is primarily expressed in the small intestinal epithelium and appears to function as a negative regulator of T-cell activation (12), with mutations in this protein conferring increased risk of inflammatory bowel disease (IBD) (13).”
Background
Metadata
- Authors
- Arnett, H. A., Escobar, S. S., Gonzalez-Suarez, E., Budelsky, A. L., Steffen, L. A., Boiani, N., Zhang, M., Siu, G., Brewer, A. W., & Viney, J. L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-02-01
- Volume
- 178
- Issue
- 3
- Pages
- 1523-1533
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1954884893
- Cited by
- 139
- References
- 7
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.